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Interventional activation of the carotid baroreﬂex has been an appealing idea for the management of resistant hypertension
for several decades, yet its clinical application remained elusive and a goal for the future. It is only recently that the profound
understanding of the complex anatomy and pathophysiology of the circuit, combined with the accumulation of relevant
experimental and clinical data both in animals and in humans, has allowed the development of a more eﬀective and well-
promising approach. Indeed, current data support a sustained over a transient reduction of blood pressure through the resetting
of baroreceptors, and technical deﬁcits have been minimized with a subsequent recession of adverse events. In addition, clinical
outcomes from the applicationof a new implantabledevice (Rheos) that induces carotid baroreceptor stimulationpoint towards a
safe and eﬀective blood pressure reduction, but longer experience is needed before its integration in the everyday clinical practice.
While accumulating evidence indicates that carotid baroreceptor stimulation exerts its beneﬁts beyond blood pressure reduction,
further research is necessary to assess the spectrum of beneﬁcial eﬀects and evaluate potential hazards, before the extraction of
secure conclusions.
1.Introduction
Arterial hypertension represents a major public health prob-
lem around the word. Currently, more than one billion peo-
ple are thought to have hypertension worldwide and the
number is estimated to exceed 1.5 billion by 2025 [1]. The
advent of antihypertensive therapy has provided drugs that
eﬀectivelylowerblood pressure and contributedsigniﬁcantly
to the reduction of cardiovascular events [2]. The rates
of awareness, treatment, and control of hypertension have
been constantly increased over the last decades; they remain,
however, far from optimal [3], underlining the need for the
implementation of more eﬀective approaches.
Antihypertensive drugs belong to diﬀerent categories,
exerting their actions through diﬀerent mechanisms that are
sometimes complimentary. It has been shown, however, that
despite the proper use of several antihypertensive agents,
blood pressure remains uncontrolled in a small percentage
of hypertensive patients (5%–15%). This subgroup has been
c a l l e do v e rt h ey e a r sa ss u ﬀering from refractory, diﬃcult
to control, or resistant hypertension (lately). Although the
percentage of this subgroup does not seem signiﬁcant, the
actual number of resistant hypertensives is estimated to be
very large due to the high prevalence of hypertension in
the general population. Therefore, the need for alternative
approaches has been widely recognized over the last several
years. This is the reason why the interventional manage-
ment of hypertension, which has been used at the mid
of the 20th century and abandoned thereafter, has rekindled
and gained intense scientiﬁc interest. In particular, carotid
baroreceptor stimulation and renal sympathetic denervation
have been tested during the last decade for the treat-
ment of resistant hypertension with promising preliminary
results.2 International Journal of Hypertension
The carotid baroreﬂex represents a signiﬁcant element
of blood pressure homeostasis. Carotid baroreceptors sense
the intra-arterial blood pressure and modulate the sym-
pathetic tone towards the opposite direction that is, high
blood pressure results in reduced sympathetic tone through
baroreceptor activation, while enhanced sympathetic tone
compensates for low blood pressure. For a long period of
time, the carotid baroreﬂex has been considered as a short-
term buﬀering system, regulating the abrupt transient ﬂuc-
tuations of blood pressure around a “constant set-point”,
while its role in the long-term regulation of blood pressure
has been signiﬁcantly questioned. Recent experimental and
clinical data however challenge this long-standing belief,
and strongly suggest the ability of the carotid baroreﬂex
to exert long-term eﬀects on blood pressure; therefore, the
interventionalactivationofthecarotidbaroreﬂex hasrevived
for the management of resistant hypertension.
This paper aims to present available data on the role of
the carotid baroreﬂex in the treatment of resistant hyper-
tension by: (a) delineating the anatomy, physiology, and
pathophysiology of the baroreﬂex arc, (b) presenting the
experience with carotid nerve activation that was used in
the 60s for the treatment of severe hypertension and other
cardiovasculardiseases, and(c)bycriticallyevaluatingrecent
experimental and clinical data with carotid baroreceptor
stimulation using the Rheos device.
2.Anatomy,Physiology,andPathophysiologyof
the CarotidBaroreﬂex
The carotid baroreﬂex circuit represents the main part of the
arterialbaroreﬂex system.Althoughperipheralbaroreceptors
canbefoundintheaorticarch, theheart, andthepulmonary
vessels, a vast amount of evidence points towards the pivotal
roleofthecarotidbaroreceptorsonbloodpressurebuﬀering.
Carotid baroreceptors are stretch-sensitive mechanosensors,
located at the right and left carotid sinus. They sense the
distention of the carotid wall and transmit signals to the
brain stem via the glossopharyngeal nerve. The nucleus
tractus solitaris (NTS) that lies in the dorsal medulla
represents the “reception center” of aﬀerent signals from
arterial baroreceptors. Signals are then neurotransmitted to
the caudal ventrolateral medulla (CVLM), which represents
the “conversion center”, since it converts the excitatory
signals from peripheral baroreceptors to inhibitory signals
that sequentially travel to the rostral ventrolateral medulla
(RVLM). The latter represents the “coordinating center”
since sympathoexcitatory neurons travel from here towards
all over the body regulating the sympathetic tone.
Actually,thebaroreﬂex circuitis much morecomplicated
than the afore-mentioned brief description. Anatomical
crossovers, intersections, and bypasses exist, while a great
variety of peptides are used as neurotransmitters with either
inhibiting or activating properties. Moreover, data from
anatomical, pharmacological, and electrophysiological stud-
iesaresometimes conﬂicting,mainlyduetothesophisticated
and demanding techniques that are used for these stud-
ies, thus rendering methodological problems unavoidable.
However, a detailed description of the carotid baroreﬂex is
beyond the scope of the current paper. Therefore, it can
be summarized that, irrespective of the exact nature of the
baroreﬂex circuit, the net result of baroreceptor activation is
a subsequent suppression of the sympathetic tone.
The functional evaluation of the carotid baroreﬂex has
been mainly based on suppression studies through carotid
denervation. A large amount of animal studies with carotid
d e n e r v a t i o ni nd i ﬀerent species provided essential informa-
tion regarding the role ofcarotidbaroreceptorsin theregula-
tionofbloodpressure, especially duringthelongterm.Older
studies have mainly pointed towards a transient increase
of blood pressure following baroreceptor denervation that
was not sustained during longer followup periods, despite
some opposite ﬁndings that have been reported [4–10]. A
limited role of carotid baroreﬂex in the long-term regulation
of blood pressure was further established by the landmark
study of McCubbin, which described the phenomenon of
“baroreceptor resetting” [11]. The response to the carotid
baroreﬂex is blunted in hypertensive animals suggesting a
resetting of the carotid baroreceptors towards the prevailing
pressure, which is actually very rapid and takes place within
minutes [12]. However, several concerns can be raised
regarding the denervation studies as well as the level of
baroreceptor resetting that have been recently reviewed
[13]. Indeed, recent animal studies suggest a signiﬁcant
role of the carotid baroreﬂex even in the long-term blood
pressure regulation, by using diﬀerent, more sophisticated,
methodological approaches that better resemble clinical
conditions [14–20].
Data in humans exist as well, although limited, and
derive from denervation studies reporting the eﬀects of
iatrogenicdamageofcarotidsinusduringvariousprocedures
(carotid body tumour surgery, carotid paraganglioma exci-
sion, carotid endarterectomy, and head and neck radiother-
apy). The majority of these studies failed to ﬁnd a persistent
elevation of blood pressure, despite acute transient increases
of blood pressure levels and enhanced blood pressure
variability [21–25]; however, opposite studies can be found
as well, reporting long-lasting blood pressure elevations
following carotid baroreceptor denervation [26–28]. The
above-mentioned controversialﬁndings maybeattributedto
the retrospective nature of the studies that has not permitted
for appropriate study designs.
3.CarotidNerveActivation—Experimentaland
ClinicalData
Carotid baroreﬂex activation for the treatment of resistant
hypertension does not represent a new idea. The pursuit of
blood pressure reduction through the continuous baroreﬂex
activation has ﬂourished during the 50s and 60s. Several
devices have been invented for the exogenous electrical
stimulation of the carotid nerves. The principal idea was that
an external generator transmitted signals to an implanted
receiver through an antenna coil, and the signals subse-
quently travelled to electrodest h a tw e r ep l a c e di nc o n t a c t
with the carotid sinus nerves. The concept was based onInternational Journal of Hypertension 3
the assumption that the continuous carotid nerve signalling
would be sensed by the central nervous system as a constant
rise in blood pressure, leading to sympathetic attenuation
and subsequent blood pressure reduction. This concept
created a lot of enthusiasm, and initial experimental studies
have been shortly thereafter followed by clinical studies. This
is not surprising, given the limited armamentarium for the
therapeuticmanagement of severe hypertension at that time.
Animal studies with carotid nerve activation uncovered
signiﬁcant blood pressure reduction, which was not only
transient but was maintained during the one-year followup
study period [29, 30]. The observation that electrical
carotid nerve activation acutely decreases blood pressure in
humans [31] encouraged the application of these devices in
patients with resistant hypertension. Several case series from
specialized clinics in North America have been published
during the 60s [32–37]. The results showed a consistent
blood pressure reduction in the majority of patients that
was evident rapidly and lasted during prolonged followup
periods, up to twelve years. The enthusiasm regarding this
eﬃcacious method however subsided rather rapidly, due
to the excessive incidence of adverse events and the severe
technical disadvantages of the devices.
4.CarotidBaroreceptorStimulation—
ExperimentalandClinicalData
Recentadvancesintechnologyseemtoovercomemanyofthe
prior technological problems with the devices, thus rekin-
dling the scientiﬁc interest and rendering carotid baroreﬂex
activation an appealing ﬁeld of research. A small, US-
based, pharmaceutical company (CVRx Inc, Minneapolis,
Minn) has developed an implantable device (Rheos) for the
electrical stimulation of carotid baroreceptors. In brief, a
pulse generator that resembles a pacemaker is implanted in
the right infraclavicular space and connects to two electrode
leads that are placed in the perivascular space of the two
carotid sinuses (Figure 1). The generator communicates
with an external computer system that is capable of pro-
gramming the baroreceptor activation in a noninvasive way.
The procedure requires an experienced team of surgeons,
anaesthesiologists, hypertension specialists, and technicians
for the proper placement of the electrodes, the eﬃcacy
testing, and the overall success. The properties of the
Rheos device along with the advancements in the surgical
and anesthesiology ﬁeld seem to address a lot of previous
concerns; adverse events are not encountered as frequently
as with the old devices and are mostly of less severity.
The Rheos device has been extensively tested in ani-
mals, reﬂecting current stringent requirements by regulatory
authoritiesworldwide. Carotid baroreceptorstimulation was
eﬀective in reducing blood pressure of conscious normoten-
sive dogs [38] and in obesity-induced hypertension [39]. On
the other hand, blood pressure reduction was signiﬁcantly
attenuated, but not abolished, in angiotensin II-induced
hypertension [40], suggesting that the overactivation of
the renin-angiotensin system may partially overcome the
eﬀects of the carotid baroreceptor stimulation. The clinical
Figure 1: Schematic representation of the Rheos device for carotid
baroreceptor stimulation.
signiﬁcance of this ﬁnding and the answer to the subsequent
question, whether drugs inhibiting the renin-angiotensin
axis are essential in patients undergoing carotid baroreceptor
stimulationforthemaintenance ofbloodpressurereduction,
remain to be clariﬁed. Another puzzling ﬁnding comes
from the study of carotid baroreceptor stimulation before
and after bilateral renal denervation [41]. Blood pressure
reduction with the Rheos device was unaltered by renal
denervation, casting doubts on the role of renal innervation
in mediating the eﬀects of the carotid baroreﬂex on blood
pressure regulation. However, further studiesinhypertensive
animals need to be performed to uncover the role of renal
denervation in this experimental setting. It has to be noted,
however, that in all the afore-mentioned animal studies
[38–41], the blood pressure reduction was accompanied
by a signiﬁcant decrease in plasma noradrenaline levels,
indicating that the suppression of the sympathetic tone
mediates the eﬀects of carotid baroreceptor stimulation on
blood pressure.
Studies in humans have conﬁrmed the eﬃcacy of this
interventional approach, which was observed in animals.
Acutebloodpressure reductionwasnotedbyusingtheRheos
device during elective carotid surgery [42]. Several case
reports in patients with resistant hypertension have shown
the clinical utility and long-lasting reductions in blood
pressure with carotid baroreceptor stimulation, setting the
basis for proof-of-concept, properly designed, clinical trials
[43–45]. The device based therapy of hypertension (DEBuT-
HT) trial in 45 patients with resistant hypertension revealed
a signiﬁcant reduction in both systolic and diastolic blood
pressure, which was evident from the beginning of the study
and was maintained thereafter [46]. The 3-year eﬃcacy was
recently presentedverifying thelong-lasting eﬀectsofcarotid
baropacing. Recruitment for a large randomized study has
been completed and results are still pending. Preliminary
information suggests that some patients may not respond as
well, and a more careful selection process may need to be
implemented.
Availabledatasuggestabeneﬁcialeﬀectofcarotidbarore-
ceptor stimulation on the reversal of left ventricular hyper-
trophy. Moreover, additional desirable eﬀects on cardiac4 International Journal of Hypertension
structure and function have been observed, including atten-
uated mitral A-valve velocity and reduced left atrial dimen-
sions.Whetherthesepilotﬁndingswouldbeofmajorclinical
importance remain to be further investigated. Another
important aspect relates to theeﬀectsofcarotid baroreceptor
stimulation on renal function. Available data suggests that
carotid baropacing does not impair the renal function of
patients with resistant hypertension, even during prolonged
followup periods. Two recent studies enlighten the mecha-
nisms via which carotid baroreceptor stimulation achieves
blood pressure reduction [47, 48]. Similar to ﬁndings from
animal studies, it was shown that baroreceptor stimulation
was accompanied by attenuation of sympathetic activity,
assessed by muscle sympathetic nerve activity [47]o rb y
analysis of heart rate variability [48]. Regarding safety, recent
data indicate that the Rheos device can be safely used in
patientswithpacemakers[49].Inaddition,ithasbeenshown
that the chronic stimulation of the carotid baroreceptors
does not cause injury, remodelling, or stenosis of the carotid
arteries [50].
It has to be noted that some technical issues need to
be resolved, and several clinical aspects need to be clariﬁed,
before the wide application of this interventional technique
in everyday clinical practice [13]. However, the latest con-
cerns regarding the eﬃcacy of the device underline the
need for careful evaluation of every emerging therapeutic
approach to fulﬁll the two fundamental requirements: safety
and eﬃcacy.
5.Conclusions
The carotid baroreﬂex represents an essential component
of blood pressure regulation. The activation of the carotid
baroreﬂex results in the attenuation of the sympathetic tone
and subsequent blood pressure reduction. Carotid nerve
activation has been used in the past for the treatment
of severe hypertension, but its use has been abandoned
due to adverse events and several technical disadvantages.
Recent technological advances have permitted the develop-
ment of a new device (Rheos) that electrically stimulates
carotid baroreceptors and seems to overcome prior technical
problems. Available experimental and clinical data point
towardsadequateeﬃcacywithacceptablesafetyofthisdevice
although some concerns have been raised lately. Therefore,
further studies are needed to clarify the place of carotid
baroreceptorstimulationinthemanagementofpatientswith
resistant hypertension.
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